The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).

Shunjun JiangHengrui LiangZhichao LiuShen ZhaoJun LiuZhanhong XieWei WangYalei ZhangBaohui HanJianxing HeWenhua Liang

Published in: The oncologist (2020)

Anlotinib can benefit patients with advanced NSCLC with BM and is highly potent in the management of intracranial lesions. Its special effect on BM and cerebral tissue merits further investigation. (ClinicalTrials.gov ID: NCT02388919).

Keyphrases

phase iii
brain metastases
small cell lung cancer
open label
double blind
clinical trial
placebo controlled
phase ii
subarachnoid hemorrhage
study protocol
anti inflammatory
cerebral ischemia
tyrosine kinase